Leadership & Pay ·
Contested election triggers immediate vesting of unvested awards for Principal Financial Officer Sandra Boenisch
AVXLAnavex Life Sciences Corp.
Anavex Life Sciences Corp. held its Annual Meeting of Stockholders on September 24, 2026, resulting in a contested election where six company-nominated directors were elected and none of the six nominees nominated by PVG Asset Management Corporation were selected. The contest triggered a 'Board Change Change in Control' provision under the company's incentive plans and the employment agreement with Principal Financial Officer Sandra Boenisch, causing all outstanding unvested awards to immediately vest. Voting results showed significant opposition for some directors, such as Dr. Jiong Ma receiving 37 million votes for against 14 million. The meeting also ratified Grant Thornton LLP as the independent auditor. Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases.